NeuroVive Pharmaceutical AB Publishes 2018 Annual Report

Fecha : 25/03/2019 @ 04:48
Fuente : PR Newswire (US)
Emisora : Neurovive Pharmaceutical Ab (0QDU)
Cotización : 2.65  0.0 (0.00%) @ 19:00
Neurovive Pharmaceutical... Cotización de acciones Gráfica

NeuroVive Pharmaceutical AB Publishes 2018 Annual Report

Neurovive Pharmaceutical... (LSE:0QDU)
Gráfica de Acción Histórica

1 año : De Oct 2018 a Oct 2019

Haga Click aquí para más Gráficas Neurovive Pharmaceutical....

LUND, Sweden, 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 10:00 a.m. CET on 25 March 2019.

About NeuroVive 

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for genetic mitochondrial diseases and one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). The R&D portfolio also consists of projects for genetic mitochondrial disorders, NASH and cancer. The company advances drugs for rare diseases through clinical development into the market, with or without partners. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive's NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). 

This information was brought to you by Cision,c2771265

The following files are available for download:

NeuroVive Pharmaceutical AB publishes 2018 Annual report

For more information please contact:
Catharina Johansson
IR & Communications
+46 (0)46-275-62-21 

NeuroVive Pharmaceutical AB (publ)
Medicon Village
SE-223 81 Lund, Sweden
Tel: +46 (0)46-275-62-20 (switchboard),
For news subscription, please visit  
Follow us on LinkedIn

Copyright 2019 PR Newswire

Su Consulta Reciente
Fibra Prol..
América Mó..
IPC México
United Sta..
Las acciones que ha visto aparecerán en este recuadro, lo que le permite volver fácilmente a las cotizaciones que ha consultado previamente
Registrarse ahora para crear su lista personalizada de acciones en streaming.

Cotizaciones PLUS están en tiempo real. Cotizaciones NYSE y AMEX están con retraso de por lo menos 20 minutos.
El resto de las cotizaciones están con retraso de por lo menos 15 minutos al menos que se indique lo contrario.

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

P: V:mx D:20191023 20:56:42